Skip to main content
main-content

11.04.2020 | Ausgabe 4/2020

Journal of Thrombosis and Thrombolysis 4/2020

Albumin and bleed risk in rivaroxaban treated patients

Zeitschrift:
Journal of Thrombosis and Thrombolysis > Ausgabe 4/2020
Autoren:
E. Wojakowski, C. Cheruvil, A. Hassan, M. R. Holsen, L. Chen, M. Rossi, N. Wilcox, A. E. Woodruff
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11239-020-02092-w) contains supplementary material, which is available to authorized users.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Drugs exhibiting high protein binding have potential increased action in patients with hypoalbuminemia. Rivaroxaban is 92–95% protein bound, but the clinical effects of rivaroxaban in patients with low albumin are largely unknown. The purpose of this study was to evaluate the relationship between albumin and bleeding in rivaroxaban treated patients. This was a retrospective cohort study of hospitalized adults who received rivaroxaban and had an albumin level measured during admission between January and October 2017. Patients who experienced bleeding events while receiving rivaroxaban therapy where compared to those who did not. A multivariable logistic regression model was used to evaluate the association between albumin levels and bleeding events. A total of 368 patients were included; 30 experienced a bleeding event and 338 did not. The mean ± standard deviation albumin level nearest to the time of rivaroxaban initiation was significantly lower in patients who experienced a bleeding event (3.0 ± 0.75 g/dL vs 3.66 ± 0.54 g/dL, p < 0.0001). The multivariable logistic regression model yielded an almost 4.5 fold higher risk of bleeding (adjusted odds ratio 4.405; 95% confidence interval 2.21–9) with any 1 g/dL reduction in albumin. Admission hemoglobin was also associated with bleed risk in the model. Albumin levels were significantly associated with bleed risk in patients receiving rivaroxaban. Albumin levels should be considered when evaluating candidates for rivaroxaban therapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Nur für berechtigte Nutzer zugänglich
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2020

Journal of Thrombosis and Thrombolysis 4/2020 Zur Ausgabe
  1. Sie können e.Med AINS 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise